Repository
Publications
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: a large real-life worldwide populationRimini M, Fornaro L, Rizzato M, Antonuzzo L, Rossari F, Satake T, Vandeputte H, Vivaldi C, Pressiani T, Lucchetti J, Kim J, Abidoye O, Rapposelli I, Tamberi S, Finkelmeier F, Giordano G, Nichetti F, Chon H, Braconi C, Pirrone C, Casadei-Gardini A.
|
Loss of mucosal tolerance to glycoprotein 2 isoform 1 is a potential novel diagnostic biomarker for cholangiocarcinomaXia C, Krawczyk M, Di C, Krupa Ł, Kruk B, Krawczyk P, Milkiewicz P, Bao H, He X, Liu D, Fan C, Nasser A, Lopens S, Ulrich Weiss F, Frost F, Schierack P, Roggenbuck D, Liu Y.
|
Strategies to enhance the response of liver cancer to pharmacological treatmentsMarin JJG, Macias RIR, Asensio M, Romero MR, Temprano AG, Pereira OR, Jimenez S, Mauriz JL, Di Giacomo S, Avila MA, Efferth T, Briz O.
|
Insights for clinical management from the real-life data of the centralized West of Scotland biliary cancer clinicZanuso V, Nash T, Casolino R, Armstrong G, Pallise O, Milne J, Braconi C.
|
The ABCG8 polymorphism increases the risk of gallbladder cancer in the general population and gallstones in obese patients from Poland.Krupa L, Kalinowski P, Ligocka J, Dauer M, Jankowski K, Gozdowska J, Kruk B, Milkiewicz P, Zieniewicz K, Krawczyk M, Weber SN, Lammert F, Krawczyk M.
|
